Alpha 2.0
Login Register
» Articles » PMID: 370348

Experiences with L-deprenyl in Parkinsonism

Overview
Journal J Neural Transm
Specialties Neurology
Physiology
Date 1978 Jan 1
PMID 370348
Citations 6
Authors
E CSANDA
J ANTAL
M Antony
A Csanaky
Affiliations
Soon will be listed here.
Abstract

In about 2/3 of the cases studied (152 patients), the combination of deprenyl and the substitution-therapy has a favourable effect as it tends to normalize motor activity. Although the administering of deprenyl renders neither L-Dopa nor the decarboxylase inhibitor superfluous, their side effects can be slightly reduced as their dose is reduced. Therefore it is advised to give all patients a trial with this drug.

Citing Articles

Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.

Schachter M, Marsden C, Parkes J, Jenner P, Testa B J Neurol Neurosurg Psychiatry. 1980; 43(11):1016-21.

PMID: 6777463 PMC: 490754. DOI: 10.1136/jnnp.43.11.1016.

The pharmacology of Parkinson's disease: basic aspects and recent advances.

Da Prada M, Keller H, Pieri L, Kettler R, HAEFELY W Experientia. 1984; 40(11):1165-72.

PMID: 6437857 DOI: 10.1007/BF01946641.

Anti-parkinsonian drugs today.

Quinn N Drugs. 1984; 28(3):236-62.

PMID: 6435991 DOI: 10.2165/00003495-198428030-00002.

Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.

Baraczka K, Fekete M, Kanyicska B J Neural Transm. 1983; 58(3-4):299-304.

PMID: 6420516 DOI: 10.1007/BF01252815.

Clinical pharmacokinetics of anti-parkinsonian drugs.

Cedarbaum J Clin Pharmacokinet. 1987; 13(3):141-78.

PMID: 3311529 DOI: 10.2165/00003088-198713030-00002.

References
1.
Birkmayer W, Riederer P, Youdim M, Linauer W . The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm. 1975; 36(3-4):303-26. DOI: 10.1007/BF01253131. View
2.
Birkmayer W, Riederer P, AMBROZI L, Youdim M . Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1977; 1(8009):439-43. DOI: 10.1016/s0140-6736(77)91940-7. View
3.
Lees A, Shaw K, Kohout L, STERN G, Elsworth J, Sandler M . Deprenyl in Parkinson's disease. Lancet. 1977; 2(8042):791-5. DOI: 10.1016/s0140-6736(77)90725-5. View
4.
Glover V, Sandler M, Owen F, Riley G . Dopamine is a monoamine oxidase B substrate in man. Nature. 1977; 265(5589):80-1. DOI: 10.1038/265080a0. View